论文部分内容阅读
目的探讨双歧三联活菌胶囊联合莫沙必利对便秘型肠易激综合征(IBS-C)重叠功能性消化不良(FD)患者的疗效及其对血清胃肠神经递质水平的影响。方法选择IBS-C重叠FD患者84例,随机分为观察组和对照组,每组42例。两组患者均予以莫沙必利片5mg/次,3次/d,餐前约30min口服。观察组患者在对照组基础上加用双歧三联活菌胶囊630mg/次,3次/d,餐后约30min温水服用。两组患者均治疗8周。观察并比较血清胃肠神经递质[胃动素(MTL)、P物质(SP)和生长抑素(SS)]水平的变化,并评估其临床疗效及患者不良反应。结果治疗8周后,两组患者血清MTL和SP水平显著上升,SS水平显著下降,且观察组患者指标变化比对照组更明显,差异均有统计学意义(P<0.05);同时观察组患者临床总有效率高于对照组(χ2=4.09,P<0.05)。观察组和对照组患者分别出现不良反应4例与6例,均为腹泻,症状较轻微,两组差异无统计学意义(χ2=0.45,P>0.05)。结论双歧三联活菌胶囊联合莫沙必利治疗IBS-C重叠FD疗效显著,安全性较高,能纠正患者胃肠神经递质分泌异常,上调血清MTL和SP水平,下调血清SS水平,有效促进胃肠动力。
Objective To investigate the curative effect of bifid triple-viable capsule combined with mosapride on gastrointestinal neurotransmitter in patients with congestive-type predominant irritable bowel syndrome (IBS-C) overlapping functional dyspepsia (FD). Methods 84 patients with IBS-C overlapping FD were randomly divided into observation group and control group with 42 cases in each group. Both groups were given mosapride tablets 5mg / time, 3 times / d, about 30min before meals orally. Observation group patients in the control group based on the use of bifid triple active bacteria capsule 630mg / times, 3 times / d, about 30min after taking warm water. Both groups were treated for 8 weeks. The levels of serum gastrointestinal neurotransmitters (MTL, SP and SS) in serum were observed and compared, and their clinical efficacy and adverse reactions were evaluated. Results After 8 weeks of treatment, the serum MTL and SP levels increased significantly and the SS level decreased significantly in both groups, and the changes in the observation group were more obvious than those in the control group (P <0.05). At the same time, the patients in the observation group The total clinical effective rate was higher than that of the control group (χ2 = 4.09, P <0.05). There were 4 cases and 6 cases of adverse reactions in the observation group and the control group, all of which were diarrhea with mild symptoms. There was no significant difference between the two groups (χ2 = 0.45, P> 0.05). Conclusion Bifid triple viable capsule combined with mosapride in treatment of IBS-C overlap FD is effective and safe, can correct gastrointestinal neurotransmitter secretion abnormalities, raise serum MTL and SP levels, down-regulate serum SS level, effective Promote gastrointestinal motility.